“…The ‘Access’ group are considered as first- or second-line antibiotics for up to 26 common or severe clinical syndromes, typically with a narrow spectrum and low resistance potential. The ‘Watch’ group have a higher resistance potential and side-effects, with the ‘Reserve’ group only recommended as last resort antibiotics and prioritized for Antimicrobial Stewardship Programs (ASPs) using agreed quality indicators (QIs) ( Figure 1 ) [ 55 , 56 , 57 , 58 , 59 ]. Assessing antimicrobial prescribing against current guidance, and monitoring their use based on the WHO AWaRe list, is increasingly being undertaken across Africa and beyond to improve prescribing given the extent of current prescribing of ‘Watch’ and ‘Reserve’ antibiotics in Africa [ 13 , 15 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ].…”